SCHEMBL1928039

SCHEMBL1928039

CC(Nc1nccc(Nc2c(NC(C)C(C)(C)C)c(=O)c2=O)n1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 20/20 1.00
PLK4 O00444 2/20 0.63
CHEK1 O14757 2/20 0.63
AURKA O14965 2/20 0.63
PDPK1 O15530 2/20 0.63
DAPK3 O43293 2/20 0.63
ROCK2 O75116 2/20 0.63
CHEK2 O96017 2/20 0.63
CDK1 P06493 2/20 0.63
CSF1R P07333 2/20 0.63
PIM1 P11309 2/20 0.63
FGFR1 P11362 2/20 0.63
FLT1 P17948 2/20 0.63
FGFR3 P22607 2/20 0.63
CDK2 P24941 2/20 0.63
MARK3 P27448 2/20 0.63
MAPK1 P28482 2/20 0.63
FLT4 P35916 2/20 0.63
KDR P35968 2/20 0.63
FLT3 P36888 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1928042 1.00 PLK1 (1.00) PLK1PLK4CHEK1AURKAPDPK1
SCHEMBL1927281 0.86 PLK1 (1.00) PLK1PLK4CHEK1AURKAPDPK1
SCHEMBL1927279 0.86 PLK1 (1.00) PLK1PLK4CHEK1AURKAPDPK1
SCHEMBL1926114 0.83 PLK1 (1.00) PLK1PLK4CHEK1AURKAPDPK1
SCHEMBL1926222 0.83 PLK1 (1.00) PLK1PLK4CHEK1AURKAPDPK1
SCHEMBL1926393 0.83 PLK1 (1.00) PLK1PLK4CHEK1AURKAPDPK1
SCHEMBL1925672 0.81 PLK1 (1.00) PLK1
SCHEMBL4559827 0.81 PLK1 (0.68) PLK1CSF1R
SCHEMBL4559829 0.81 PLK1 (0.68) PLK1CSF1R
SCHEMBL1926079 0.81 PLK1 (0.76) PLK1PLK4CHEK1AURKAPDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956185-B2 Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases ABBOTT LABORATORIES (US) 2011-06-07 US disclosed
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES ABBVIE INC. 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES PLK1, PLK2, BUB1B PLK1 1/4885PLK4 6/4885CHEK1 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.